WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (the “Company”) in the present day introduced its intention to voluntarily file a Kind 25 Notification of Delisting with the U.S. Securities and Trade Fee (the “SEC”) on Monday, April 20, 2026, to take away its frequent inventory from itemizing and registration on The Nasdaq Inventory Market LLC (“Nasdaq”). As beforehand disclosed, buying and selling within the Firm’s frequent inventory was suspended by Nasdaq on March 17, 2026. Though Nasdaq has indicated it intends to file its personal Kind 25 in spite of everything inner procedural durations have run, it has not but carried out so. The Firm is due to this fact voluntarily submitting Kind 25 to be able to proceed with deregistration. The Firm’s frequent inventory is at present quoted on the Pink Restricted Market. This press launch is being issued in compliance with Rule 12d2-2(c) beneath the Securities Trade Act of 1934, as amended (the “Exchange Act”).
Ahead-Trying Statements
This press launch comprises forward-looking statements inside the which means of the Personal Securities Litigation Reform Act of 1995. Ahead-looking statements on this press launch embrace, however should not restricted to, statements relating to the Firm’s intention to file Kind 25 and the anticipated timing thereof, the anticipated effectiveness of the delisting, the Firm’s plans to file a Kind 15 to terminate registration and droop reporting obligations, and the anticipated suspension and termination of periodic reporting necessities. These statements contain recognized and unknown dangers, uncertainties, and different components which will trigger precise outcomes to vary materially from these expressed or implied in such statements. Vital components that might trigger precise outcomes to vary materially from these mirrored within the Firm’s forward-looking statements are mentioned beneath the heading “Risk Factors” within the Firm’s Annual Report on Kind 10-Ok for the fiscal yr ended December 31, 2025, and in different filings the Firm makes with the SEC every so often. The Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions, or in any other case, besides as required by relevant regulation.
